Biweekly vs Triweekly low dose intravenous ketamine acute series for severe major depression: A case report

Bahji, 2021, Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis, J. Affect. Disord., 278, 542, 10.1016/j.jad.2020.09.071 Baudot, 2022, Safety concerns on the abuse potential of esketamine: multidimensional analysis of a new anti-depressive drug on the market, Fundam. Clin. Pharmacol., 36, 572, 10.1111/fcp.12745 Busner, 2007, Global impressions scale: applying a research, Psychiatry, 4, 28 Dominiak, 2021, Efficacy, safety and tolerability of formula-based unilateral vs bilateral electroconvulsive therapy in the treatment of major depression: a randomized open label controlled trial, J. Psychiatr. Res., 133, 52, 10.1016/j.jpsychires.2020.12.002 Green, 2015, The predictive validity of the beck depression inventory suicide item, J. Clin. Psychiatry, 76 Gutierrez, 2022, Efficacy and tolerability of two novel “Standard of Care” treatments-intranasal esketamine versus intravenous ketamine-for treatment-resistant depression in naturalistic clinical practice: protocol for a pilot observational study, JMIR Res. Protoc., 11, 10.2196/34711 Montgomery, 1979, Scale designed to be sensitive to change, Br. J. Psychiatry, 134, 382, 10.1192/bjp.134.4.382 Morrens, 2022, Use of Clinical Global Impressions-Severity (CGI-S) to assess response to antidepressant treatment in patients with treatment-resistant depression, Neuropsychiatr. Dis. Treat., 18, 1127, 10.2147/NDT.S358367 Østergaard, 2016, Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS), J. Affect. Disord., 190, 111, 10.1016/j.jad.2015.09.073 Phillips, 2020, Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial, Focus, 18, 236, 10.1176/appi.focus.18206 2021 Sapkota, 2021, Efficacy and safety of intranasal esketamine in treatment-resistant depression in adults: a systematic review, Cureus, 13 Shah, 2016, Novel approaches for managing treatment-resistant depression, Psychiatr. Ann., 46, 220, 10.3928/00485713-20160229-01 Short, 2018, Side-effects associated with ketamine use in depression: a systematic review, Lancet Psychiatry, 5, 65, 10.1016/S2215-0366(17)30272-9 Singh, 2016, A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression, Am. J. Psychiatry, 173, 816, 10.1176/appi.ajp.2016.16010037 Steer, 1999, Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients, J. Clin. Psychol., 55, 117, 10.1002/(SICI)1097-4679(199901)55:1<117::AID-JCLP12>3.0.CO;2-A Vazquez, 2022, Association of intranasal esketamine, a novel “standard of care” treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice, BMJ Open, 12, 1, 10.1136/bmjopen-2022-060967 Vázquez, 2021, Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium, J. Psychopharmacol., 35, 890, 10.1177/02698811211013579 World Health Organization. Depression 2020. https://www.who.int/news-room/fact-sheets/detail/depression. Yavi, 2022, Ketamine treatment for depression: a review, Discov. Ment. Heal., 2